Pleasant Grove, Utah (Hexa PR Wire — October 2, 2026) —
The Pentagon’s new testosterone screening guidance is bringing hormone health into sharper public focus. For Rob Jones, M.D., CEO of Hormone Balance Centers, the development highlights a leadership challenge facing specialist healthcare businesses: turning increased awareness into informed medical decisions rather than treating every new inquiry as a prescription opportunity.
Guidance released in September 2026 calls for male service members aged 30 and older to undergo testosterone deficiency screening during periodic health assessments, entry examinations, or annual physicals. Younger men can be screened on request or when a clinician identifies relevant indicators.
Importantly, the Defense Health Agency describes screening as a structured assessment of symptoms and risk factors. That is not the same as automatically ordering blood tests for everyone or prescribing testosterone replacement therapy, commonly called TRT. Treatment remains an individualized decision between patients and medical professionals.
Jones provides clinical oversight and guidance at Hormone Balance Centers, a Utah-based practice that describes its approach as treating the person rather than an isolated laboratory number. Its care model combines clinical evaluation, appropriate testing, telehealth consultations, and ongoing monitoring when treatment is prescribed.
For a healthcare executive, that distinction has practical consequences. Patient education, appointment workflows, prescribing decisions, and follow-up systems should reinforce the same message: access to care is valuable, but access without appropriate evaluation is not a sufficient measure of success. The military announcement makes that challenge especially visible.
The medical debate also demands careful communication. In a July statement, the Endocrine Society said evidence was insufficient to support population-level testosterone blood screening in asymptomatic men. It emphasized that diagnosis requires compatible symptoms and consistently low hormone measurements, with at least two early-morning, fasting testosterone tests.
That caution does not dismiss patients’ concerns. It establishes a framework for investigating them. Fatigue, low libido, and changes in mood can have multiple causes, and clinicians should consider reversible contributors rather than assuming testosterone is the answer. For Jones and other healthcare leaders, clear explanations can help separate legitimate evaluation from unrealistic expectations.
Fertility is another important consideration. The Endocrine Society recommends against starting testosterone therapy in men planning fertility in the near term. Counseling about reproductive goals, potential risks, and monitoring belongs within the treatment decision, not after a patient has already committed to a program.
Hormone Balance Centers has published a guide to military testosterone testing and TRT that explains the new policy, the difference between screening and diagnosis, and considerations for service members exploring private care. The resource also makes clear that HBC is not a replacement for military medical care or an endorsed Pentagon provider.
That boundary matters. TRICARE states that active-duty service members need referrals for most care outside their assigned military hospital or clinic. Increased publicity around hormone health does not remove those requirements or turn a civilian provider into part of the military’s screening program. HBC’s published patient journey offers a concrete example of how a practice can organize its response: begin with questions, determine appropriate laboratory testing, review symptoms and medical history, and develop an individualized plan when treatment is warranted. Its telehealth services are available to eligible patients in Utah and Idaho.
The broader leadership opportunity is not to promise that hormone treatment will improve everyone’s performance. It is to build an organization capable of listening, explaining uncertainty, and following patients beyond the first consultation. As military screening attracts attention, Jones’s clinical oversight role illustrates why the quality of the care process deserves as much attention as the treatment itself. For healthcare businesses, the strongest response to a national headline may be a consistently careful, transparent patient experience built around each individual’s needs.
